Prednisolone metasulfobenzoate sodium controlled-release - Alizyme

Drug Profile

Prednisolone metasulfobenzoate sodium controlled-release - Alizyme

Alternative Names: ATL-2502; COLAL-PRED; TSD-0011

Latest Information Update: 20 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alizyme
  • Developer Alizyme; Norgine; Prometheus Laboratories; TSD Japan
  • Class Anti-inflammatories; Antiallergics; Antirheumatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Ulcerative colitis

Most Recent Events

  • 31 Jul 2011 Prometheus Laboratories has been acquired by Nestle
  • 25 Feb 2011 Suspended - Phase-II for Ulcerative colitis in USA (PO)
  • 20 Dec 2010 No development reported - Phase-I for Ulcerative colitis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top